On the same day President Trump stirred controversy by linking autism risk to acetaminophen use during pregnancy, the FDA announced it would approve a new use for leucovorin, or folinic acid, to treat children with cerebral folate deficiency, an ultra-rare disorder that can present with autism-like features.
What caught physicians’ attention most, however, was the rhetoric during the September 22 press conference—and in an accompanying press release—in which senior administration health officials suggested that leucovorin could be offered to a much broader group of children with autism.Read the rest of the article from mdlinx.com here.